The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity

Clinical and Experimental Rheumatology

Volumn 20, Issue 2, 2002, Pages 221-224

  Toubi, E ^a   Kessel, A ^a   Grushko, G ^a   Sabo, E ^a   Rozenbaum, M ^a   Rosner, I ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Disease severity; Matrix metalloproteinases; Scleroderma

Indexed keywords

INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME SYNTHESIS; FEMALE; HEART FAILURE; HUMAN; LUNG FIBROSIS; MALE; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; BLOOD; CLASSIFICATION; EVALUATION; HOSPITALIZATION; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0035990178     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts
2. Proteinases and matrix degradation
3. Discordinate expression of Stromelysin, collagenase, and tissue inhibitor of metalloproteinases 1 in human rheumatoid synovial fibroblasts. Synergistic effects of IL-1 and TNF-α on stromelysin expression
4. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
5. Constitutive expression of 92-kDa gelatinase by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines
6. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinase-1 in sera from patients with rheumatoid arthritis
7. Elevated plasma stromelysin levels in arthritis
8. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis
9. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis
10. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatic arthritis
11. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts
12. Measurement of matrix metalloproteinases and tissue inhibitors of MMPs in blood and tissues. Clinical and experimental applications
13. Rheumatoid arthritis cells produce Th1 cytokines in response to stimulation with a novel trispecific antibody directed against CD2, CD3, and CD23
14. Type2 helper T-cell predominance and high CD30 expression in systemic sclerosis
15. The American Rheumatism Association 1987 revised criteria for the classification of RA
16. Scleroderma (systemic sclerosis), classification, subsets and pathogenesis
17. A disease severity scale for systemic sclerosis: Development and testing
18. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in SLE
19. Interleukin-2, Interleukin-4, Interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma
20. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts
21. Increased interferon-gamma levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynauds phenomena
22. Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritis
23. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis
24. Activation of fibroblasts in collagen lattices by mast cell extract; a model of fibrosis
25. Effect of heparin on the production of matrix metalloproteinases and tissue inhibitors of metalloproteinases by human dermal fibroblasts
26. Excess matrix accumulation i scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis